Perspectives on the implementation of post-validation surveillance for lymphatic filariasis in the Pacific Islands: A Nominal Group Technique-based study protocol

Adam T Craig^{1,*}, Harriet Lawford¹, Satupaitea Viali^{2,3}, George Tuitama², Colleen L Lau¹

¹UQ Centre for Clinical Research, The University of Queensland, ²Oceania University of Medicine Samoa, ³National University of Samoa. *Corresponding author

Abstract

Introduction: Lymphatic filariasis (LF) is a neglected tropical disease caused by parasitic worms, transmitted via mosquito bites. Significant global efforts have led to the interruption of LF transmission, with eight of the 16 previously endemic Pacific Island countries and territories (PICTs) validated by WHO as having eliminated the disease as a public health problem. Post-validation surveillance (PVS) is recommended to verify the absence of a resurgence in transmission; however, there are no guidelines on how to implement such surveillance effectively.

Aim: This protocol outlines a research study that aims to explore, synthesise, and prioritise the perspectives of LF program staff from LF-eliminated PICTs. The study will focus on identifying the challenges faced in implementing PVS in the PICT settings and determining corresponding context-relevant operational research priorities.

Method: The study will employ a nominal group technique (NGT) involving representatives from LF-eliminated PICTs. The NGT will adhere to a structured process for generating, ranking, and prioritising ideas, followed by group discussions, debates, and the collation of shared views.

Discussion: The research will provide insights into the most significant challenges faced in implementing PVS in the PICTs. It will also identify priority areas where operational research is required to inform policy and practice. To our knowledge, this study is the first to apply a rigorous consensus group method to distil challenges and research priorities for LF PVS in PICTs. We expect this research to inform the development of national and regional LF guidelines.

Keywords: Lymphatic filariasis, surveillance, post-validation surveillance, Pacific Islands, operational research, disease elimination, infectious diseases, neglected tropical diseases, Nominal Group Technique.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Introduction

Consensus group methods are widely used to synthesise expert opinions when evidence is insufficient or conflicting. These methods have been applied across multiple disciplines, including healthcare, education, engineering, and management [1, 2], to inform a variety of health-related activities. These include defining diagnostic criteria, classifying diseases, selecting quality indicators, informing management guidelines, and educating healthcare professionals [1-5].

Nominal group technique (NGT) was originally developed for effective group decision-making within social psychological research [3]. The NGT follows a structured format to generate, rank, or prioritise ideas. The process typically involves presenting a nominal question; participants generating and reporting of ideas; group clarification, debate, and discussion; ranking and voting; and results and conclusion generation [6]. NGT is recognised for adhering to the foundational principles of consensus decision-making methods [2].

One distinctive feature of NGT is its emphasis on structured discussion and debate, which allows diverse ideas on shared interests to be expressed, explored, and collated. Where differences in opinion arise, the reasons for these can be discussed. This collaborative approach has been suggested to enhance stakeholders' sense of ownership over the resulting research and increase the likelihood of influencing practice or policy change [3]. While NGT's structured nature and engagement are key advantages, its limitations include the relatively small number of participants and the potential for dominant voices to influence group decisions.

Lymphatic filariasis (LF) is a neglected tropical disease (NTD) caused by three species of filarial worm: Wuchereria bancrofti, Brugia malayi, and B. timori and transmitted between humans by a range of mosquito species including Aedes, Culex, and Anopheles [7, 8]. W. bancrofti is the only filarial worm species found in the Pacific Islands [9]. Adult worms reside in the lymphatic system and can cause chronic damage over time if left untreated.

Lymphatic filariasis has affected about 882 million people, primarily in tropical and subtropical regions of Africa, Southeast Asia, the Pacific Islands, and the Americas [10]. As of 2018, 51 million people were infected – a 74% decline since the start of WHO's Global Programme to Eliminate Lymphatic Filariasis in 2000 [11]. Since 2000, over 9.7 billion treatments for LF have been administered through mass drug administration (MDA) campaigns, reaching more than 943 million people. In 2023, the number of people that require MDA was 657 million [13].

The Pacific Islands include 22 small island countries and territories located over one-third of the Earth's surface and are home to around 15 million people [14]. In 2000, the Global Programme to Eliminate LF (GPELF) was launched by the World Health Organization (WHO). The GPELF's main objective was to achieve the elimination of LF as a public health problem across 73 endemic nations, including 16 in the Pacific Islands region, by 2020 [15]. [16] Through multiple rounds of MDA over many years, eight previously endemic Pacific Island Countries and Territories (PICTs) have reduced the prevalence of LF to below the microfilaria-positive prevalence threshold of 1% where transmission is thought to be no longer sustainable [17]. The WHO has validated these countries as having achieved the elimination of LF as a public health problem. Eight other PICTs have yet to eliminate LF, and six are considered non-endemic for LF (Table 1) with no recorded evidence of LF transmission [13].

Table 1. Pacific Island Country and Territory lymphatic filariasis endemicity and elimination status (2024).

Pacific	Year	Mid-year	Year most	Summary of findings				
island	validated	population	recent					
countries	by WHO	estimate	published					
and	as having	(2022)#	survey was					
territories	eliminated		conducted [^]					
(PICTs)	LF							
PICTs that h	PICTs that have eliminated LF as a public health problem							
Cook	2016	15,406	2013-14 [18]	2,903 participants from ten islands were tested. Only one person (an adult) was antigen				
Islands				(Ag) positive for LF. No Ag-positive individuals were found on the other 11 islands. The				
				national Ag prevalence was calculated at 0.23%.				
Niue	2016	1,543	2009 [19]	A whole-population survey (n=1,378) found an overall LF Ag prevalence of 0.5% with no				
				cases in six to seven-year-old children.				
Vanuatu	2016	307,941	2010-12 [20]	4,480 school-aged children were surveyed in three sampling units; no Ag-positive cases				
1				were found. Subsequently, a transmission assessment survey was conducted in one				
				sampling unit that found two Ag-positive children out of 933 tested. The national Ag				
				prevalence was calculated at 0.2%.				
Wallis and	2016	11,304	2012 [21]	A survey of 939 school-age children found three were Ag-positive cases, giving an overall				
Futuna				Ag prevalence of 0.3%.				
Palau	2017	17,976	2001 [22]	A baseline assessment survey conducted in 2001 found nine Ag-positive cases (all from				
				the same village) out of 2,031 people examined. The Ag prevalence was calculated at				
				0.4%.				
Tonga	2017	99,283	2015 [23]	The survey of 2,806 children from across all five administrative divisions found one Ag-				
				positive case, giving an overall Ag prevalence of 0.04%.				
Marshall	2017	54,446	2003 [22]	A 2001 baseline assessment survey of 2,003 people on two islands found two positive				
Islands				cases on Mejit Island, giving an Ag prevalence of 0.1%. In 2002, a blood antigen survey on				
				Mejit and Alluk islands found 130 Ag-positive cases among 294 people (44.2%) and 71				
				Ag-positive cases among 244 (29%), respectively. A similar survey conducted in 2003				
				found no positive cases among 217 people examined on Wotje Atoll and the 318 people				
			_	examined on Ebon Atoll.				
Kiribati	2019	122,735	1999-2000 [22]	A baseline assessment A survey found an Ag prevalence of 1.7%.				
PICTs that have not yet eliminated lymphatic filariasis as a public health problem								

American	-	57,085	2016 [24, 25]	135 of 2,671 survey participants were Ag-positive giving an Ag prevalence of 5.1%,
Samoa				confirming ongoing LF transmission in previously known clusters and hotspots, and
				identifying new potential hotspots that warrant investigation.
Fiji	-	901,603	2007 [26]	A nationwide stratified cluster survey found the Ag prevalence to be 9.5%, ranging from
				0.9% in the Western Division to 15.4% in the Eastern Division. Microfilaria (Mf) prevalence
				was 1.4%.
French	-	280,855	2008 [27]	A cross-sectional, stratified, three-cluster sampling study of inhabitants aged 2 years and
Polynesia				older found an ICT-positive prevalence of 11.3% and Mf-prevalence of 10%.
Federated	-	105,987	2003 [28]	A survey of 233 participants on Satawal Islands found 96 (38%) were Ag-positive. 55
States of				(22%) were found to have circulating Mf.
Micronesia				
New	-	274,330	2013 [29]	A survey of 1,035 participants identified seven Ag-positive cases. All participants tested
Caledonia				negative for Mf blood smears and filarial DNA. The overall LF Ag prevalence was 0.62%
				(95% CI [0.60-0.63]). Although this is below the WHO threshold for elimination, the
				absence of epidemiological evidence excluding potential domestic transmission has
				prompted health authorities to consider the possibility of ongoing disease circulation.
Papua	-	9,311,874	Multiple years	Multiple surveys using different methods have been conducted in different locations.
New			[30, 31]	Graves et al. (2013) summary showed LF prevalences of 30.4–64.7% for the period 1983–
Guinea				92, 30.1–56.9% for the period 1993–2000, and 7.8–12.8% for the period 2003–11.
Samoa	-	200,999	2023 [32]	623 participants aged >5 years from 125 randomly selected households in eight sampling
				units were surveyed. Ag-positive cases were found in six of the eight sampling units. The
				adjusted Ag prevalence was 9.9% (95% CI 3.5-21.0).
Tuvalu	-	10,778	2004 [22]	A whole-population serosurvey found 973 Ag-positive cases among 8,173 people tested,
				giving an Ag-positive prevalence of 11.9%.

PICTs where lymphatic filariasis is not endemic

Guam (population: 179,900); Nauru (11,974); Northern Mariana Islands (56,986); Pitcairn Island (50), Solomon Islands (744,407); Tokelau (1,497).

Footnote: #Source: [33]. Population figures are mid-year estimates based on interpolating nations' census data and projections. The futures may differ from the actual census count in census years due to adjustments made by the Pacific Data Hub to allow comparability. ^The information presented is derived from publicly available sources. More recent but unpublished results may also exist. Additionally, some data pertain to specific sampling units or subsets within a country, and, as such, readers are advised to refer to the source document (cited) for a detailed account of the sampling frame used and results.

Countries that have received WHO validation of elimination of LF as a public health problem are encouraged to conduct periodic post-validation surveillance (PVS) to ensure that LF transmission has not been re-established; however, to date, there are no official WHO guidelines on how best or how frequently to conduct PVS [8].

Aim

This manuscript presents the study protocol for research that will use NGT to explore, synthesise, and prioritise the views of NTD program staff from LF-eliminated PICTs regarding the challenges faced in implementing surveillance for LF. Building on the main challenges identified, the study aims to develop a list of priority operational research questions that, once answered, will inform context-relevant policy and programmatic design. Further, the findings from this research are expected to inform national and regional LF guideline development, including the 'in draft' WHO guidelines for PVS of LF.

Methods

Participant recruitment and target sample size

A letter inviting participation in the NGT will be sent by email to national NTD program staff from LF-eliminated PICTs who are registered to attend the Coalition for Operational Research into Neglected Tropical Diseases (COR-NTD) meeting for the Pacific Islands in Brisbane, Australia on 25-26 September 2024. The letter will explain the study's objectives, rationale, risks, and benefits for participants. It will also provide a study participant information sheet and consent form and convey that the study has received ethical approval from The University of Queensland Human Research Ethics Committee. The timing of the NGT is opportunistic, as representatives from across the PICTs will be attending the COR-NTD meeting.

We aim to have one or two representatives from each PICT that has eliminated LF as a public health problem in the study (i.e., a purposefully selected sample of eight to 16). We propose to limit NGT discussion groups to a maximum of ten participants (i.e., if >10 participants elect to participate, two groups of NGT discussion will be formed).

Eligibility criteria

To be eligible for the NGT, a participant must have at least two years' experience with their national NTD program and, during this time, have been involved in LF-related planning, surveillance, or response activities.

Consent process

A study participant information sheet and consent form will be attached to the email sent to participants. The email will request that the consent form be returned before the NGT. Verbal confirmation of consent will be obtained at the start of NGT, and participants will be advised that they can withdraw their consent at any time without prejudice. Consent will also be obtained to audio-recorded the NGT session.

We do not anticipate that participants will experience harm or psychological distress because of participating in the NGT. Participants are health professionals who routinely engage in stakeholder consultation activities.

Ethics

This study has the approval of The University of Queensland's Human Research Ethics Committee (Project# 2024/HE000224).

Nominal group technique implementation

Room set-up, equipment, and facilitation

The NGT will take place during a 2-hour face-to-face meeting. Participants will be arranged in a circle to ensure an egalitarian atmosphere, eliminating any sense of dominance or hierarchy. Each participant will receive a clipboard, adhesive note paper (i.e., a 'Post-it' notepad), and a pen. Additionally, a space on the wall will be designated for displaying and making participant-generated ideas visible to everyone.

One researcher will facilitate the NGT, guiding the process and providing explanations. A co-investigator will assist the facilitator as needed.

Introducing the NGT process

At the start of the NGT, the facilitator will welcome the participants and invite them to introduce themselves, serving as an icebreaker. The facilitator will then spend 5-10 minutes explaining the purpose of the research and providing a step-by-step overview of the NGT process. This explanation will be supported by a visual aid and a simple example to ensure clarity. Participants will be invited to ask questions and seek clarification throughout this introductory phase.

Step 1. Presentation of a nominal question, group members idea generation, clarification

To begin, the facilitator will present a nominal question verbally and on a poster for visibility. The question will be: "What do you consider to be the most significant challenges you face, or anticipate facing, in implementing PVS for LF in your setting?" Participants will be reminded that the aim is to gather the full range of responses, and that no response is wrong.

Participants will then have 2 minutes to reflect on the question and make individual notes. Following this, the facilitator will invite one participant to share one of their responses. This response will be clarified, recorded briefly on a Post-it note, and displayed on the wall. Participants will be limited to one response at a time to ensure dominant voices do not overpower others' ability to make contributions. The facilitator will continue to invite participants, one-by-one, to contribute one response at a time until all responses are captured. This may take several 'rounds' of idea generation.

Once all responses are displayed, participants will gather around the wall. The facilitator will prompt the group to identify overlapping responses and suggest possible merges. Participants will also be encouraged to seek clarification on any responses and revise wording if necessary. Participants will be invited to add any new ideas they may have, which will be incorporated into the display.

Step 2. Individual ranking

The next step of the NGT involves participants reflecting on and ranking the responses generated by the group. This will be done individually using a simple voting method developed by Delbecq [34], where each participant is allocated a set number of votes (e.g., ten) to distribute among the ideas as they choose. Participants may allocate all votes to one idea or distribute them across multiple ideas according to their perspectives.

The votes will be collected and tallied once all participants have completed the ranking. During this process, participants will be invited to take a 5-minute break. Upon their return, the facilitator will arrange the Post-it notes displaying the ideas in rank order. Ideas resonating most with the group are expected to appear higher in the order, while those considered less critical will rank lower. The facilitator will emphasise that the rankings are relative and that a lower rank does not imply the idea is unimportant.

The facilitator will then open a discussion about the rankings, asking questions such as, "Is this what you expected?" or "Would those who ranked this idea highest like to explain their reasoning?" If significant differences in opinion arise, the discussion will continue, and participants will have the option to repeat the ranking exercise if they are willing (i.e., conduct Step 2 again).

Step 3. Scoping priory research questions related to highly ranked challenges

The final step of the NGT will focus on generating operational research questions identified by national officers. The facilitator will invite participants to reframe the three highest-ranking responses to the nominal question into operational research questions. Given the uncertainty surrounding the nature of the emerging questions and the limited time available, a specific framework for drafting operational research questions is not proposed at this stage. Such refinement will occur at a later point.

When addressed, these questions will provide critical, context-specific insights to inform LF surveillance practices and strategy development across the PICTs. We recognise that identifying and refining operational research priorities, as well as securing political and financial commitments for action, is a time-intensive process. Therefore, we propose this stage of the NGT be the initial step towards developing a Pacific officer-led operational research agenda for LF.

Analysis

The ranking data will be quantitatively described, while discussions regarding the prioritisation, rationale for decision-making, and sentiments expressed will be qualitatively analysed using an inductive thematic approach, as outlined by Braun and Clarke [35], and Terry and colleagues [36]. Comparisons will be made between groups based on LF status, recency of LF surveillance activities, and demographic and economic factors, among other relevant variables.

Discussion

This research aims to gather insights into the primary challenges faced by health officers in PICTs that have eliminated LF, particularly regarding PVS. Additionally, it will initiate discussions on the research priorities of national health officers related to LF surveillance, with

the goal of generating knowledge that is directly relevant to PICTs' policy and practice for LF surveillance.

Consensus group methods are widely employed to identify and assess areas where evidence is incomplete [5, 37, 38]. While numerous consensus methods have been developed, including the Delphi technique, the Consensus Development Conference approach, and the Research and the Development/University of California Los Angeles (RAND/UCLA) Appropriateness method [38], NGT was chosen for this study as it facilitates rapid, time-bound group decisions. Its structure enables real-time feedback and controlled interaction, ensuring all voices in the group contribute equally. The participants in the NGT are experts in LF surveillance in their relevant context, which positively influences the findings' validity, credibility, reliability, and acceptability [38]. Key advantages of NGT include the generation of numerous ideas in a relatively short timeframe [39], equal participation and prioritisation of ideas, 'ownership' of the outcomes, and immediate feedback [35]. Noted limitations include a relatively small number of participants and a facilitator, as well as the need to overcome logistical challenges, such as the need for participants to be in the same location [39].

To the best of our knowledge, this study represents the first application of a methodologically rigorous consensus group method to gather insights and identify operational research priorities for surveillance of LF, or any other disease, in the PICTs. Consequently, it will offer a novel approach to stakeholder consultation for end-user priority setting that will inform future program design. Specifically, the findings from this research are expected to inform national and regional LF PVS guideline development, including the 'in draft' WHO guidelines for PVS of LF.

References

- 1. Murphy M, Black N, Lamping D, McKee C, Sanderson C, Askham J, et al. Consensus development methods, and their use in clinical guideline development. Health Technology Assessment (Winchester, England). 1998;2(3):i-88. doi: doi.org/10.3310/hta2030. PMCID: PMC9561895.
- 2. Jones J, Hunter D. Consensus methods for medical and health services research. BMJ. 1995;311(7001):376-80. Epub 1995/08/05. doi: 10.1136/bmj.311.7001.376. PubMed PMID: 7640549.
- 3. Harvey N, Holmes CA. Nominal group technique: an effective method for obtaining group consensus. Int J Nurs Pract. 2012;18(2):188-94. Epub 2012/03/23. doi: 10.1111/j.1440-172X.2012.02017.x. PMID: 22435983.
- 4. Humphrey-Murto S, Ho Lee S, Gottlieb M, Horsley T, Shea B, Fournier K, et al. Protocol for an extended scoping review on the use of virtual nominal group technique in research. PLoS One. 2023;18(1):e0280764. Epub 2023/01/21. doi: 10.1371/journal.pone.0280764. PMID: 36662907.
- 5. Humphrey-Murto S, Varpio L, Wood TJ, Gonsalves C, Ufholz LA, Mascioli K, et al. The Use of the Delphi and Other Consensus Group Methods in Medical Education Research: A Review. Acad Med. 2017;92(10):1491-8. Epub 2017/07/06. doi: 10.1097/ACM.00000000001812. PMID: 28678098.
- 6. Campbell SM, Cantrill JA. Consensus methods in prescribing research. J Clin Pharm Ther. 2001;26(1):5-14. Epub 2001/04/05. doi: 10.1046/j.1365-2710.2001.00331.x. PMID: 11286603.
- 7. Lawford H, Mayfield H, Sam FA, Viali S, Kamu T, Cooley G, et al. Anti-filarial antibodies are sensitive indicators of lymphatic filariasis transmission and enable identification of highrisk populations and hotspots. Int J Infect Dis. 2024;147:107194. Epub 2024/07/30. doi: 10.1016/j.ijid.2024.107194. PMID: 39074737.
- 8. Lawford H, Tukia, Takai J, Sheridan S, Lau CL. Operational research to inform post-validation surveillance of lymphatic filariasis in Tonga study protocol: History of lymphatic filariasis elimination, rational, objectives, and design. PLoS One. 2024;19(8):e0307331. Epub 2024/08/20. doi: 10.1371/journal.pone.0307331. PMID: 39163407.
- 9. Gordon CA, Jones MK, McManus DP. The History of Bancroftian Lymphatic Filariasis in Australasia and Oceania: Is There a Threat of Re-Occurrence in Mainland Australia? Tropical Medicine and Infectious Disease. 2018;3(2):58. doi:10.3390/tropicalmed3020058. PMID: 30274454.
- 10. Antony Oliver MC, Graham M, Gass KM, Medley GF, Clark J, Davis EL, et al. Reducing the Antigen Prevalence Target Threshold for Stopping and Restarting Mass Drug Administration for Lymphatic Filariasis Elimination: A Model-Based Cost-effectiveness Simulation in Tanzania, India and Haiti. Clinical Infectious Diseases. 2024;78(Supplement_2):S160-S8. doi: 10.1093/cid/ciae108. PMID: 38662697.
- 11. World Health Organization. Global Programme to Eliminate Lymphatic Filariasis: progress report, 2019. Weekly Epidemiological Record. 2020;95(43):509-23.
- 12. Zeldenryk LM, Gray M, Speare R, Gordon S, Melrose W. The emerging story of disability associated with lymphatic filariasis: a critical review. PLoS Negl Trop Dis. 2011;5(12):e1366. Epub 2012/01/05. doi: 10.1371/journal.pntd.0001366. PMID: 22216361.
- 13. World Health Organization. Global Programme to Eliminate Lymphatic Filariasis: progress report, 2023. Weekly epidemiological record. 2024;99(99):565-76. Epub 04/10/2024.
- 14. Craig AT, Kaldor J, Schierhout G, Rosewell AE. Surveillance strategies for the detection of disease outbreaks in the Pacific islands: meta-analysis of published literature, 2010-2019. Trop Med Int Health. 2020;25(8):906-18. Epub 2020/05/24. doi: 10.1111/tmi.13448. PMID: 32446271.

- 15. World Health Organization. Lymphatic filariasis: monitoring and epidemiological assessment of mass drug administration: a manual for national elimination programmes. Geneva, Switzerland: WHO. 2011.
- 16. World Health Organization. Global Programme to Eliminate Lymphatic Filariasis. Weekly epidemiological record. 2010;85(38):365-72. PMCID: PMC20853547.
- 17. World Health Organization. Global Programme to Eliminate Lymphatic Filariasis: monitoring and epidemiological assessment of mass drug administration. World Health Organization, Geneva, Switzerland. 2011.
- 18. Ave C, Kapa DR, Ottesen E. Elimination of lymphatic filariasis as a public health problem from the Cook Islands. Trop Med Health. 2018;46(1):12. Epub 2018/05/23. doi: 10.1186/s41182-018-0094-9. PMID: 29785168.
- 19. Carlingford CN, Melrose W, Mokoia G, Graves PM, Ichimori K, Capuano C, et al. Elimination of lymphatic filariasis as a public health problem in Niue under PacELF, 1999-2016. Trop Med Health. 2019;47(1):20. Epub 2019/03/30. doi: 10.1186/s41182-019-0141-1. PMID: 30923457.
- 20. Taleo F, Taleo G, Graves PM, Wood P, Kim SH, Ozaki M, et al. Surveillance efforts after mass drug administration to validate elimination of lymphatic filariasis as a public health problem in Vanuatu. Trop Med Health. 2017;45:18. Epub 2017/06/21. doi: 10.1186/s41182-017-0057-6. PMID: 28630586.
- 21. Pezzoli L, Kim SH, Mathelin JP, Hennessey K, Eswara Aratchige P, Valiakolleri J. An Expanded Transmission Assessment Survey to Confirm the Interruption of Lymphatic Filariasis Transmission in Wallis and Futuna. Am J Trop Med Hyg. 2019;101(6):1325-30. Epub 2019/10/10. doi: 10.4269/ajtmh.19-0476. PMID: 31595868.
- 22. World Health Organization. The PacELF way: Towards the elimination of lymphatic filariasis from the Pacific, 1999-2005. Manila: WHO Regional Office for the Western Pacific; 2006.
- 23. Ofanoa R, Ofa T, Padmasiri E, Kapa DR. Elimination of lymphatic filariasis as a public health problem from Tonga. Tropical Medicine and Health. 2019;47:1-10. doi: 10.1186/s41182-019-0169-2. PMID: 31346312.
- 24. Wangdi K, Sheel M, Fuimaono S, Graves PM, Lau CL. Lymphatic filariasis in 2016 in American Samoa: Identifying clustering and hotspots using non-spatial and three spatial analytical methods. PLoS Negl Trop Dis. 2022;16(3):e0010262. Epub 2022/03/29. doi: 10.1371/journal.pntd.0010262. PMID: 35344542.
- 25. Cadavid Restrepo AM, Martin BM, Fuimaono S, Clements ACA, Graves PM, Lau CL. Spatial predictive risk mapping of lymphatic filariasis residual hotspots in American Samoa using demographic and environmental factors. PLoS Negl Trop Dis. 2023;17(7):e0010840. Epub 2023/07/24. doi: 10.1371/journal.pntd.0010840. PMID: 37486947.
- 26. Manolas RK, Kama M, Rainima-Qaniuci M, Bechu VD, Tuibeqa S, Winston MV, et al. Lymphatic filariasis in Fiji: progress towards elimination, 1997-2007. Trop Med Health. 2020;48(1):88. Epub 2020/11/03. doi: 10.1186/s41182-020-00245-4. PMID: 33132735.
- 27. Mou Y, Plichart C, Legrand A-M, Mallet H-P, Cerf N, Nguyen LN. Evaluation de la prévalence de la filariose lymphatique en 2008 en Polynésie française. Bull Epidémiol Hebd. 2009;48:504-7.
- 28. Pretrick M, Melrose W, Chaine JP, Canyon D, Carron J, Graves PM, et al. Identification and control of an isolated, but intense focus of lymphatic filariasis on Satawal Island, Federated States of Micronesia, in 2003. Trop Med Health. 2017;45(1):17. Epub 2017/06/16. doi: 10.1186/s41182-017-0050-0. PMID: 28615988.
- 29. Daures M, Champagnat J, Pfannstiel A, Ringuenoire F, Grangeon JP, Musso D. Filariasis serosurvey, New Caledonia, South Pacific, 2013. Parasit Vectors. 2015;8(1):102. Epub 2015/04/19. doi: 10.1186/s13071-015-0713-9. PMID: 25889011.

- 30. Graves PM, Makita L, Susapu M, Brady MA, Melrose W, Capuano C, et al. Lymphatic filariasis in Papua New Guinea: distribution at district level and impact of mass drug administration, 1980 to 2011. Parasites & vectors. 2013;6:1-18. doi: 10.1186/1756-3305-6-7. PMID: 23311302.
- 31. Berg Soto A, Xu Z, Wood P, Sanuku N, Robinson LJ, King CL, et al. Combining different diagnostic studies of lymphatic filariasis for risk mapping in Papua New Guinea: a predictive model from microfilaraemia and antigenaemia prevalence surveys. Trop Med Health. 2018;46(1):41. Epub 2018/12/12. doi: 10.1186/s41182-018-0123-8. PMID: 30533996.
- 32. Mayfield HJ, Sartorius B, Sheridan S, Howlett M, Martin BM, Thomsen R, et al. Ongoing transmission of lymphatic filariasis in Samoa 4.5 years after one round of triple-drug mass drug administration. PLoS Negl Trop Dis. 2024;18(6):e0012236. Epub 2024/06/27. doi: 10.1371/journal.pntd.0012236. PMID: 38935622.
- 33. Pacific Community. Pacific Data Hub: Population Dashboard. Nouméa, New Caledonia: SPC; 2024 [cited 2024 21/10/2024]. Available from: https://pacificdata.org/population-dashboard.
- 34. Manera K, Hanson CS, Gutman T, Tong A. Consensus Methods: Nominal Group Technique. In: Liamputtong P, editor. Handbook of Research Methods in Health Social Sciences. Singapore: Springer Singapore; 2019. p. 737-50.
- 35. Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Research in Psychology. 2006;3(2):77-101. doi: 10.1191/1478088706qp063oa.
- 36. Terry G, Hayfield, Nikki, Clarke, Victoria, Braun, Virginia Thematic Analysis. In: Willig CR, W, editor. The SAGE Handbook of qualitative research in psychology. London: SAGE Publications Ltd; 2017. p. 17-36.
- 37. Humphrey-Murto S, Varpio L, Gonsalves C, Wood TJ. Using consensus group methods such as Delphi and Nominal Group in medical education research(). Med Teach. 2017;39(1):14-9. Epub 2016/11/15. doi: 10.1080/0142159x.2017.1245856. PMID: 27841062.
- 38. Arakawa N, Bader LR. Consensus development methods: Considerations for national and global frameworks and policy development. Research in Social and Administrative Pharmacy. 2022;18(1):2222-9. doi: 10.1016/j.sapharm.2021.06.024. PMID: 34247949.
- 39. McMillan SS, King M, Tully MP. How to use the nominal group and Delphi techniques. International journal of clinical pharmacy. 2016;38(3):655-62. doi: 10.1007/s11096-016-0257-x. PMID: 26846316.